Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria

J Allergy Clin Immunol Pract. May-Jun 2016;4(3):529-30. doi: 10.1016/j.jaip.2015.11.025. Epub 2015 Dec 24.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-Allergic Agents / therapeutic use
  • Basophil Degranulation Test / methods
  • Basophils / immunology*
  • Biomarkers / analysis
  • Chronic Disease
  • Drug Monitoring / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Omalizumab / therapeutic use*
  • Phosphoric Diester Hydrolases / analysis*
  • Pyrophosphatases / analysis*
  • Reproducibility of Results
  • Retrospective Studies
  • Urticaria* / diagnosis
  • Urticaria* / drug therapy
  • Urticaria* / immunology

Substances

  • Anti-Allergic Agents
  • Biomarkers
  • ENPP3 protein, human
  • Omalizumab
  • Phosphoric Diester Hydrolases
  • Pyrophosphatases